Aligos Therapeutics Inc (ALGS)vsModerna Inc (MRNA)
ALGS
Aligos Therapeutics Inc
$5.22
-2.06%
HEALTHCARE · Cap: $33.28M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 6969% more annual revenue ($2.23B vs $31.52M). MRNA leads profitability with a -141.4% profit margin vs -241.0%. ALGS earns a higher WallStSmart Score of 39/100 (F).
ALGS
Hold39
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.0%
Fair Value
$62.23
Current Price
$5.22
$57.01 discount
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 2779.0% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -284.1% — below average capital efficiency
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALGS
The strongest argument for ALGS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 2779.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ALGS
The primary concerns for ALGS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ALGS profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
ALGS carries more volatility with a beta of 2.33 — expect wider price swings.
ALGS is growing revenue faster at 2779.0% — sustainability is the question.
ALGS generates stronger free cash flow (-25M), providing more financial flexibility.
Bottom Line
ALGS scores higher overall (39/100 vs 21/100) and 2779.0% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aligos Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?